Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.

Journal Article

Chronic graft-versus-host disease (cGVHD) of the skin is a serious cause of long-term morbidity and mortality among patients who receive hematopoietic stem cell transplants. Systemic corticosteroids remain first-line treatment for cutaneous cGVHD; however, there is currently no consensus on second-line therapy for steroid-refractory disease. We herein present a case of a pediatric patient with severe cGVHD of the skin, nonresponsive to corticosteroids, who was successfully treated with a prolonged course of ruxolitinib with minimal side effects.

Full Text

Duke Authors

Cited Authors

  • Belina, ME; Driscoll, TA; Blanchard, SK; Cardones, AR

Published Date

  • May 2022

Published In

Volume / Issue

  • 39 / 3

Start / End Page

  • 432 - 433

PubMed ID

  • 35234308

Electronic International Standard Serial Number (EISSN)

  • 1525-1470

Digital Object Identifier (DOI)

  • 10.1111/pde.14965


  • eng

Conference Location

  • United States